Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Dec;72(6):1357–1363. doi: 10.1038/bjc.1995.515

Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.

G T Rogers 1, P J Burke 1, S K Sharma 1, R Koodie 1, J A Boden 1
PMCID: PMC2034085  PMID: 8519645

Abstract

The effect of anti-enzyme antibody clearance on prodrug turnover in antibody-directed enzyme prodrug therapy (ADEPT) has been studied. Mice bearing LS174T xenografts were given localising carboxypeptidase G2 (CPG)2 conjugate (AEC) and 19 h later galactosylated anti-CPG2 antibody (SB43-GAL). In regimen I prodrug was injected 5 h after SB43-GAL as previously described. In regimen 2 and 3 a shortened and extended clearance time was used in which prodrug was administered 0.5 h or 53 h after SB43-GAL respectively. Regimen 1 resulted in similar tumour and normal tissue levels of active drug to those of the control in which prodrug was given 72 h after AEC. SB43-GAL therefore accelerated clearance of enzyme allowing early administration of prodrug. In regimen 2, very high active drug levels were found in the liver, showing removal of AEC from the blood followed by reactivation of enzyme and extensive and rapid prodrug turnover. Active drug levels in tumour and blood reached similar peak levels to those of the control. Regimen 3 resulted in lower active drug levels in tissues, consistent with degradation and excretion of enzyme. Regimen 3 also produced the best tumour to normal ratios for active drug. Residual prodrug in tumour was unaffected by SB43-GAL, showing the advantage of galactosylation in minimising inactivation of CPG2 in tumour. By contrast, residual prodrug in blood persisted for longer when SB43-GAL was used. Circulatory clearance of enzyme with SB43-GAL allows prodrug to be administered expediently with reduced toxicity and with the prospect of increasing the dosage.

Full text

PDF
1357

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoniw P., Springer C. J., Bagshawe K. D., Searle F., Melton R. G., Rogers G. T., Burke P. J., Sherwood R. F. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br J Cancer. 1990 Dec;62(6):909–914. doi: 10.1038/bjc.1990.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bagshawe K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987 Nov;56(5):531–532. doi: 10.1038/bjc.1987.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jain R. K. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):85–100. doi: 10.1080/09553009114551621. [DOI] [PubMed] [Google Scholar]
  5. Kerr D. E., Garrigues U. S., Wallace P. M., Hellström K. E., Hellström I., Senter P. D. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjug Chem. 1993 Sep-Oct;4(5):353–357. doi: 10.1021/bc00023a008. [DOI] [PubMed] [Google Scholar]
  6. Mattes M. J. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J Natl Cancer Inst. 1987 Oct;79(4):855–863. [PubMed] [Google Scholar]
  7. McCullough J. L., Chabner B. A., Bertino J. R. Purification and properties of carboxypeptidase G 1 . J Biol Chem. 1971 Dec 10;246(23):7207–7213. [PubMed] [Google Scholar]
  8. Melton R. G., Boyle J. M., Rogers G. T., Burke P., Bagshawe K. D., Sherwood R. F. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods. 1993 Jan 14;158(1):49–56. doi: 10.1016/0022-1759(93)90257-8. [DOI] [PubMed] [Google Scholar]
  9. Paganelli G., Malcovati M., Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun. 1991 Mar;12(3):211–234. doi: 10.1097/00006231-199103000-00006. [DOI] [PubMed] [Google Scholar]
  10. Pedley R. B., Dale R., Boden J. A., Begent R. H., Keep P. A., Green A. J. The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumor xenograft model. Int J Cancer. 1989 Apr 15;43(4):713–718. doi: 10.1002/ijc.2910430429. [DOI] [PubMed] [Google Scholar]
  11. Senter P. D., Saulnier M. G., Schreiber G. J., Hirschberg D. L., Brown J. P., Hellström I., Hellström K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sharma S. K., Bagshawe K. D., Burke P. J., Boden J. A., Rogers G. T., Springer C. J., Melton R. G., Sherwood R. F. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer. 1994 Feb 1;73(3 Suppl):1114–1120. doi: 10.1002/1097-0142(19940201)73:3+<1114::aid-cncr2820731352>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  13. Sharma S. K., Bagshawe K. D., Burke P. J., Boden R. W., Rogers G. T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer. 1990 May;61(5):659–662. doi: 10.1038/bjc.1990.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sharma S. K., Bagshawe K. D., Springer C. J., Burke P. J., Rogers G. T., Boden J. A., Antoniw P., Melton R. G., Sherwood R. F. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers. 1991 May-Aug;9(3-4):225–231. [PubMed] [Google Scholar]
  15. Springer C. J., Antoniw P., Bagshawe K. D., Searle F., Bisset G. M., Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem. 1990 Feb;33(2):677–681. doi: 10.1021/jm00164a034. [DOI] [PubMed] [Google Scholar]
  16. Springer C. J., Bagshawe K. D., Sharma S. K., Searle F., Boden J. A., Antoniw P., Burke P. J., Rogers G. T., Sherwood R. F., Melton R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer. 1991;27(11):1361–1366. doi: 10.1016/0277-5379(91)90010-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES